ストックスクリーナーアプリを入手
0.63
0.16%
-0.001
Chromocell Therapeutics Corp (CHRO) 最新ニュース
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - The Manila Times
Chromocell Therapeutics Corporation Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - Marketscreener.com
Chromocell to Present at Upcoming Fall Investor Conferences - The Manila Times
Chromocell announces amendment to stock repurchase plan - MSN
Chromocell Therapeutics amends stock repurchase plan - TradingPedia
Chromocell boosts stock buyback plan to $750,000 - Investing.com India
Chromocell Announces Amendment to Stock Repurchase Plan - The Manila Times
Chromocell boosts stock buyback plan to $750,000 By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Upward Trajectory: Chromocell Therapeutics Corp. (CHRO) Posts a Slidee, Closing at 0.84 - The Dwinnex
CHRO’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Chubb (CB) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Stocks of Chemours Company (CC) are poised to climb above their peers - SETE News
Chubb Limited [CB] stock was sold by GREENBERG EVAN G at the price of US$8.78 million - Knox Daily
Recent 4.1% pullback isn't enough to hurt long-term Calumet (NASDAQ:CLMT) shareholders, they're still up 373% over 5 years - Yahoo Finance
Calumet Specialty Products Partners (NASDAQ:CLMT) Shares Gap Down to $18.00 - Defense World
Market Update: Calumet Inc. (CLMT) Sees Negative Movement, Closing at 18.00 - The Dwinnex
C.H. Robinson Worldwide Sees Unusually High Options Volume (NASDAQ:CHRW) - MarketBeat
CHRS stock touches 52-week low at $1.01 amid market challenges - Investing.com India
CG Oncology initiated with an Outperform at RBC Capital - TipRanks
Comparing BioLargo (NASDAQ:BLGO) and Chemours (NYSE:CC) - Defense World
Chubb Stock Trading Near 52-Week High: What Should Investors Know? - Yahoo Finance
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Morningstar
Choreo LLC Purchases New Stake in C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) - Defense World
Cosmic CRF shares hit 5% upper circuit on Rs 127-crore order win; details - Business Standard
CorMedix stock soars to 52-week high, hits $7.29 By Investing.com - Investing.com Australia
Investor’s Delight: Calumet Inc. (CLMT) Closes Weak at 18.24, Down -0.27 - The Dwinnex
Analyzing Calumet Inc. (CLMT) After Recent Trading Activity - Knox Daily
Another Delaware Publicly Traded Company Proposes A Nevada Move - The National Law Review
Coherus BioSciences, Inc. (NASDAQ:CHRS) Has Found A Path To Profitability - Simply Wall St
Chubb (CB) Rises Higher Than Market: Key Facts - Yahoo Finance
Chromocell therapeutics CEO buys $5,044 in company stock By Investing.com - Investing.com Canada
Chromocell therapeutics director buys $9.8k in stock - Investing.com
Chromocell therapeutics CEO buys $5,044 in company stock - Investing.com India
Chubb Ltd. stock rises Monday, outperforms market - MarketWatch
Life Sciences Virtual Investor Forum Agenda Announced for September 19th - GlobeNewswire
Chromocell to Participate in Life Sciences Investor Forum September 19th - GlobeNewswire
Calumet Specialty Products Partners (NASDAQ:CLMT) Shares Gap Down to $16.58 - Defense World
Chromocell Therapeutics CEO buys shares worth over $10,000 By Investing.com - Investing.com Australia
Market Recap Check: Calumet Inc. (CLMT)’s Positive Finish at 16.58, Up/Down 10.31 - The Dwinnex
Chromocell Therapeutics CEO buys shares worth over $10,000 - Investing.com
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online
Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q2 2024 - MSN
Chromocell announces $250,000 stock repurchase plan By Investing.com - Investing.com Australia
Chromocell Therapeutics announces stock repurchase plan up to $250,000 - TipRanks
Chromocell Therapeutics Co.’s Lock-Up Period Will End on August 14th (NYSE:CHRO) - Defense World
Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet - CNBC
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Benzinga
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga
Chutes & Ladders—Bayer undergoes leadership shake-up - Fierce Biotech
Are there bright times for biotech IPOs ahead? - European Biotechnology News
Sidoti Events, LLC's Virtual March Small-Cap Conference - Yahoo Finance
Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million - StockTitan
CHRO IPO NewsPain relief biotech Chromocell Therapeutics prices IPO at $6 midpoint - Renaissance Capital
Biotech Venture in the UAE Validated by IPO in the U.S. - PR Newswire
Chromocell Announces Initiation of Multiple Ascending Doses Portion of Phase 1 Clinical Trial - PR Newswire
Chromocell Appoints Heikki Mansikka, M.D., Ph.D., Vice President of Clinical Development - PR Newswire
Chromocell and Astellas Announce FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN - PR Newswire
Food for thought How biotech Chromocell impacts the flavor of your meals - NJBIZ
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):